The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Health-care companies fell amid concerns about increased regulation and upheaval in the sector. UnitedHealth Group continued its retreat after the abrupt departure of its chief executive.

U.S. health secretary Robert F. Kennedy Jr. said on Wednesday that the "central focus" of the National Institutes of Health ...

China-based Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong initial public offering, according to a regulatory filing made on Thursday.

The Japanese company reported higher quarterly earnings, supported by its music and movie businesses. The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 ...